MedTrace Logo

Development of a Next Generation Sequencing (NGS) -Based Assay to Detect Preeclampsia Molecular Markers

NCT02808494 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 242

Last updated 2022-04-29

No results posted yet for this study

Summary

Sample Collection Study

Conditions

Sponsors & Collaborators

  • Illumina, Inc.

    lead INDUSTRY

Principal Investigators

  • Matthew Rhoa, MD · Illumina, Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-11-20
Completion
2017-11-20

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02808494 on ClinicalTrials.gov